Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882896 | 0.84 | PTK2 (0.59) | PTK2GAACYP1A2KMT2ATDP1 | |
| SCHEMBL3301252 | 0.84 | PTK2 (0.59) | PTK2GAACYP1A2KMT2ATDP1 | |
| SCHEMBL5689275 | 0.83 | NPC1 (0.41) | PTK2KMT2ATDP1RAB9ANPC1 | |
| SCHEMBL21678138 | 0.83 | NPC1 (0.43) | PTK2TDP1RAB9ANPC1MAPT | |
| SCHEMBL2035206 | 0.82 | KDR (0.44) | PTK2CYP1A2TDP1RAB9ANPC1 | |
| SCHEMBL9769174 | 0.82 | ALDH1A1 (0.49) | RAB9ANPC1MAPTL3MBTL1KDM4E | |
| SCHEMBL8019000 | 0.79 | PTK2 (0.53) | PTK2GAACYP1A2KMT2ATDP1 | |
| SCHEMBL4391108 | 0.79 | GCK (0.57) | PTK2GAACYP1A2RAB9ANPC1 | |
| SCHEMBL4391105 | 0.79 | GCK (0.57) | PTK2GAACYP1A2RAB9ANPC1 | |
| SCHEMBL9000490 | 0.79 | PTK2 (0.53) | PTK2GAACYP1A2KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES INC. | 2013-08-08 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013037755-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-6124457-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6090942-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-07-18 | — | — | US | disclosed |
| CN-1256276-A | Intermediate of beta 3-adrenalin energy receptor protagonist and its synthesis method | PFIZER PRODUCTS CO (US) | 2000-06-14 | — | — | CN | disclosed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| CN-1237160-A | Process for preparing substituted pyridines | PFIZER (US) | 1999-12-01 | — | — | CN | disclosed |
| EP-0938476-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998021184-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | PTK2 1850/4885GAA 2626/4885CYP1A2 2499/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | PTK2 1850/4885GAA 2626/4885CYP1A2 2499/4885 |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | PTK2 1850/4885GAA 2626/4885CYP1A2 2499/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | PTK2 1850/4885GAA 2626/4885CYP1A2 2499/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | PTK2 1850/4885GAA 2626/4885CYP1A2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.